EATG » News

Webinar: Results of the METRODORA research on the involvement of women in HIV clinical trials

EATG will host a webinar on the Results of the METRODORA research on the involvement of women in HIV clinical trials on Wednesday, 02 May 2018, 13:00 – 14:00 CEST…

Webinar: Introduction to medicine research and development

EATG will host a webinar, Introduction to medicine research and development, on Thursday, 26 April 2018, 18:00 – 19:00 CEST (Brussels, Berlin, Paris time). The webinar will be led by…

Positive Stories: the voices of women living with HIV across Europe

The EATG has launched a new initiative aiming to give women living with or affected by HIV a platform to make their voices heard. Positive Stories is an empowerment tool…

Grindr sharing the HIV status and other personal information of their users with third parties without their informed consent is unacceptable

The EATG is disturbed by the news, reported by BuzzFeed News, about Grindr sharing the HIV status information of their users with two third companies, Apptimize and Localytics. Such actions…

PARADIGM: A collaborative initiative on patient engagement kicks-off

PARADIGM (Patients Active in Research and Dialogues for an Improved Generation of Medicines), a new initiative regarding patient engagement in research and development of medicines, was launched this week during…

STEP-UP 2018/19: Call for participants

The European AIDS Treatment Group (EATG) is happy to launch the call for participants for the STEP-UP 2018/19 training programme today. The STEP-UP programme is designed for people living with…

Metrodora: Webinar on women’s participation in HIV research

EATG will host a webinar on women’s participation in HIV research on 4 April 2018, 17:00 – 18:00 CET (Brussels, Berlin, Paris time). The webinar is organized within the context…

Civil society and patient organisations are seeking EU leadership and action on HIV, Hepatitis and TB

The European AIDS Treatment Group, along with other civil society and patients organisations, has co-signed an open letter to Commissioner Andriukaitis in view of the upcoming Staff Working Document on…

Organisations are urging Commissioner Andriukaitis to foster EU Member States’ response to Tuberculosis

In view of upcoming World Tuberculosis (TB) Day on March 24, the TB Europe Coalition, supported by 34 civil society and community organisations, urge Commissioner Andriukaitis to make a public…

Call for WHO & UNODC to revise guidelines on International Standards for the Treatment of Drug Use Disorders

The European AIDS Treatment Group together with 188 organisations has co-signed an open letter initiative by the International Network of People who use Drugs addressed to the WHO and UNODC…

HIVACAR: EATG reports from the second general assembly of the consortium

On March 15-16 the European AIDS Treatment Group participated in the second general assembly meeting of the HIVACAR consortium in Digem (Belgium). The EATG in collaboration with the Complutense University…

Webinar: Patient-reported Outcomes (PROs)

We invite you to join the webinar on What are patient-reported outcome measures and how are they used in drug development? taking place on Tuesday, 27 March 2018, 18:00 –…

THE EU CIVIL SOCIETY FORUM ON HIV, TB AND VIRAL HEPATITIS URGES THE EUROPEAN COMMISSION TO PRIORITIZE PUBLIC HEALTH WITHIN THE UPCOMING FINANCIAL FRAMEWORK

On 6 March the EU Civil Society Forum on HIV, TB and Viral Hepatitis wrote to the European Commission President Juncker, as well as Budget and Health Commissioners, in response to the…

Metrodora: Call for applications in the Multi-Stakeholders’ Meeting

Call for applications: Multi-Stakeholders’ Meeting Meaningful Engagement of Women in HIV Treatment Research Wednesday 16 May 2018, Park Inn Hotel, Brussels, Belgium   The Meeting: Within the framework of the…

The EU Civil Society Forum on HIV, TB and Viral Hepatitis calls the Romanian Ministry of Health to take on a leadership role on EU viral hepatitis policies

On 26 February, the EU Civil Society Forum on HIV, TB and Viral Hepatitis wrote to the Romanian Ministry of Health to request that it uses its convening power and…

HIV prevention: It’s time to stop accepting the status quo, PrEP Summit concludes

The biggest barrier to HIV pre-exposure prophylaxis (PrEP) becoming more available and more widely used is not cost so much as widespread acceptance of the status quo in HIV prevention,…

Community reception at CROI 2018

You are invited to the annual Community reception at CROI on 6 March 2018! For full details, please download the invitation for the event here: Community reception at CROI 2018,…

Presentations from the PrEP Summit now online

Organised jointly by EATG, AVAC, AIDSfonds, AIDES, AIDS Action Europe, NAM-AIDSMAP, NAT, Prepster, UNAIDS, WHO, the European PrEP Summit was organised in Amsterdam on 9-10 February 2018. The more than…

Advancing Community Agency – EATG Stakeholder Meeting in Brussels

The European AIDS Treatment Group held its annual Stakeholder Meeting in Brussels on 22 January 2018. The event welcomed 21 guests - partners and funders of EATG - who met…

M-Care 2018: Call for participants

The European AIDS Treatment Group (EATG) and the Africa Advocacy Foundation (AAF) are announcing a call for participants for the M-Care 2018 training programme. The goal of the training is…

European Union Standards for Tuberculosis Care – 2017 update

The European Centre for Disease Prevention and Control (ECDC) and the European Respiratory Society (ERS) have developed 21 patient-centred standards to guide clinicians and public health workers in their work…

Fact sheet: The U.S. government and global TB efforts

The Kaiser Family Foundation released an updated fact sheet ahead of the UN High-Level Meeting on TB, explaining the U.S. government’s role in addressing global TB, including the history of…

ViiV Healthcare submits regulatory application to EMA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV

London, UK 14 September 2018 – ViiV Healthcare today announced submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for a single-tablet, two-drug regimen of dolutegravir (DTG)…

CATIE statements on HIV prevention: updated August 2018

Over the past several years the HIV prevention toolbox has expanded significantly. This is due to a rapid growth in our knowledge of effective approaches that help prevent the transmission…

HIV and aging: A growing population faces unique challenges

A conversation with community advocate Jeff Taylor Jeff Taylor, incoming Co-chair of the Community Advisory Board of the amfAR Institute for HIV Cure Research, has been living with HIV for…

HCV-positive organs: A viable option for uninfected transplant patients

The number of hepatitis C-infected organs viable for transplantation has increased in recent years in correlation with the increasing opioid epidemic. While it is common practice to offer HCV-positive organs…

Hepatitis B and C epidemiology in selected population groups in the EU/EEA

The findings presented in this report will be part of the process of developing a European guidance for HBV and HCV testing and may provide support EU/EEA countries in the…

Epidemiological update: Hepatitis A outbreak in the EU/EEA mostly affecting MSM

As of 7 September 2018, the number of outbreak-confirmed cases reported in 22 EU/EEA countries since 1 June 2016 is 4 475. Since the last epidemiological update on this multi-country…

EPO upholds Gilead patent on hep C medicines, but in amended form

The European Patent Office (EPO) on 13 September ruled in favour of pharmaceutical company Gilead and maintained the company’s patent on hepatitis C drug sofosbuvir. The patent, however, is maintained…

CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests

On 25th July 2018, the Court of Justice of the European Union (CJEU) rendered its preliminary ruling on the interpretation of Article 3(a) of Regulation (EC) No 469/2009 concerning the supplementary protection…

Video SNiP: PET scan “hot spots” help visualize inflammatory complication of HIV

Dolutegravir results in low-resource setting highlight benefits

A standard of care treatment in high-income settings, the benefits of dolutegravir-based treatments for HIV have been clear, with a built-in barrier to the development of drug-resistance, and a less…

Innovative nanochannel delivery implant may deliver long-term HIV PrEP

A nanochannel delivery implant (NDI) can deliver pre-exposure prophylaxis (PrEP) antiretroviral (ARV) drugs subcutaneously, according to results published in the Journal of Controlled Release. PrEP with ARVs can prevent HIV transmission…

Anogenital warts may act as portals for HIV transmission

Significantly higher HIV-target cell concentrations are found in anogenital warts than in normal, site-matched skin, suggesting that anogenital warts may promote the sexual transmission of HIV, according to a study…

Dexamethasone slows fungal clearance, results in poor outcomes in HIV-associated meningitis

According to study findings published in Clinical Infectious Diseases, treatment with the anti-inflammatory steroid dexamethasone is associated with slowed clearance of fungal infections in HIV-associated cryptococcal meningitis. Additionally, the use of…

Aptima and RealTime assay have high concordance in monitoring HIV viral load

The Aptima® (Hologic) assay has 6-sigma performance, high concordance with the RealTime (Abbott Molecular) reference assay, and is user friendly and efficient, making it a good choice for laboratories that…

Egypt launches largest screening campaign for hepatitis C in the world

Egypt will launch the largest medical screening campaign for Hepatitis C in the world by applying a new initiative to detect and treat Hepatitis C to almost 50 million citizens,…

Global Fund partnership has saved 27 million lives

Half of Europe’s clinical trials fail to report results despite EU rule

LONDON, September 13, 2018 - Almost half of all European-registered clinical trials - in which scientists test drug treatments, interventions or therapies in humans - have breached EU rules by failing…

Largest study of ‘post-treatment controllers’ reveals clues about HIV remission

Some HIV patients maintain low viral loads after stopping treatment; early treatment and HIV reservoir size may be the keys Most HIV patients need to take daily anti-retroviral therapy -…